MétaCan
Menu
Back to cohort
Record W2922206684 · doi:10.1093/eurheartj/ehz119

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy

2019· article· en· W2922206684 on OpenAlexfundno aff
Sunao Kojima, Kunihiko Matsui, Shinya Hiramitsu, Ichiro Hisatome, Masako Waki, Kazuaki Uchiyama, Naoto Yokota, Eiichi Tokutake, Yutaka Wakasa, Hideaki Jinnouchi, Hirokazu Kakuda, Takahiro Hayashi, Naoki Kawai, Hisao Mori, Masahiro Sugawara, Yusuke Ohya, Kazuo Kimura, Yoshihiko Saito, Hisao Ogawa

Bibliographic record

VenueEuropean Heart Journal · 2019
Typearticle
Languageen
FieldMedicine
TopicGout, Hyperuricemia, Uric Acid
Canadian institutionsnot available
FundersSanofi K.K.Pfizer JapanBoehringer Ingelheim JapanAstellas Foundation for Research on Metabolic DisordersKyowa Hakko KirinTeijin PharmaDaiichi-SankyoMinistry of Education, Culture, Sports, Science and TechnologyMSD K.K.Asahi Kasei Pharma CorporationAstellas Pharma USKowa CompanyChugai PharmaceuticalEisai CanadaMitsubishi Tanabe Pharma CorporationNihon Medi-PhysicsTakeda Pharmaceutical CompanyDaiichi Sankyo EuropeKowa Pharmaceutical EuropeMedtronicDainippon Sumitomo PharmaPfizerNovartis PharmaOtsuka PharmaceuticalJapan Agency for Medical Research and DevelopmentBoston Scientific Japan
KeywordsMedicineFebuxostatInternal medicineHyperuricemiaUric acid

Abstract

fetched live from OpenAlex

AIMS: To compare the occurrence of cerebral, cardiovascular, and renal events in patients with hyperuricaemia treated with febuxostat and those treated with conventional therapy with lifestyle modification. METHODS AND RESULTS: This multicentre, prospective, randomized open-label, blinded endpoint study was done in 141 hospitals in Japan. A total of 1070 patients were included in the intention-to-treat population. Elderly patients with hyperuricaemia (serum uric acid >7.0 to ≤9.0 mg/dL) at risk for cerebral, cardiovascular, or renal disease, defined by the presence of hypertension, Type 2 diabetes, renal disease, or history of cerebral or cardiovascular disease, were randomized to febuxostat and non-febuxostat groups and were observed for 36 months. Cerebral, cardiovascular, and renal events and all deaths were defined as the primary composite event. The serum uric acid level at endpoint (withdrawal or completion of the study) in the febuxostat (n = 537) and non-febuxostat groups (n = 533) was 4.50 ± 1.52 and 6.76 ± 1.45 mg/dL, respectively (P < 0.001). The primary composite event rate was significantly lower in the febuxostat group than in non-febuxostat treatment [hazard ratio (HR) 0.750, 95% confidence interval (CI) 0.592-0.950; P = 0.017] and the most frequent event was renal impairment (febuxostat group: 16.2%, non-febuxostat group: 20.5%; HR 0.745, 95% CI 0.562-0.987; P = 0.041). CONCLUSION: Febuxostat lowers uric acid and delays the progression of renal dysfunction. REGISTRATION: ClinicalTrials.gov (NCT01984749).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.315
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations231
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicGout, Hyperuricemia, Uric AcidFrench-language works237,207